(WSH) Willis Group Buys Stake in South Africa
Willis Europe BV, a division of Willis Group Holdings plc (WSH), announced that Willis South Africa has acquired 22.5% of the equity in Amabubesi Consulting Services (ACS). ACS, a specialist employee...
View Article(AZN) AstraZeneca’s Brilinta Now in US
AstraZeneca plc (AZN) recently announced the US launch of Brilinta (ticagrelor). The drug was approved by the US Food and Drug Administration (FDA) last month, to reduce the rate of heart attack and...
View Article(AZN) AstraZeneca Coverage Initiated at Neutral
We are initiating coverage on AstraZeneca (AZN) with a Neutral recommendation and a target price of $47.00. AstraZeneca, headquartered in London, UK, is one of the largest biopharmaceutical companies...
View Article(XRX) Xerox Buys The Breakaway Group
Xerox Corp. (XRX) recently announced that one of its fully owned subsidiaries, Affiliated Computer Services (ACS), has acquired The Breakaway Group with the sole intent of expanding its electronic...
View Article(AZN) Good News for AstraZeneca
Good news flowed in at AstraZeneca (AZN) with the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) panel of experts updating their guidelines and issuing a class 1...
View Article(ACS) Omnicare Seals Distribution Rights
Advanced Care Scripts (ACS), a part of Omnicare Inc.’s (OCR) Specialty Care Group, has been recently included in the limited distribution network for Lundbeck’s Xenazine (tetrabenazine). Xenazine is...
View Article(ACS) Omnicare Inks Distribution Deal
Advanced Care Scripts (ACS), a part of Omnicare Inc.’s (OCR) Specialty Care Group, has been recently included in the limited distribution network for Medivation (MDVN) and Astellas Pharma’s Xtandi...
View Article(XOMA) XOMA’s Gevokizumab Study Update
XOMA Corporation (XOMA) recently announced interim data from a phase II proof-of-concept (POC) study on gevokizumab, which is being developed for the treatment of inflammatory facial lesions in...
View Article
